Truist on Boston Scientific (BSX): 'PEN Acquisition To Strengthen BSX's Path Fwd'
Tweet Send to a Friend
Truist Securities analyst Richard Newitter reiterated a Buy rating and $120.00 price target on Boston Scientific (NYSE: BSX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
